Cargando…
Targeting GITR in cancer immunotherapy – there is no perfect knowledge
Glucocorticoid-induced TNFR-related protein (GITR) belongs to the TNFR superfamily (TNFRSF) and stimulates both the acquired and innate immunity. GITR is broadly expressed on immune cells, particularly regulatory T cells (Tregs) and natural killer (NK) cells. Given its potential to promote T effecto...
Autores principales: | Davar, Diwakar, Zappasodi, Roberta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278658/ https://www.ncbi.nlm.nih.gov/pubmed/37335294 http://dx.doi.org/10.18632/oncotarget.28461 |
Ejemplares similares
-
New emerging targets in cancer immunotherapy: the role of GITR
por: Buzzatti, Giulia, et al.
Publicado: (2020) -
Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors
por: Davar, Diwakar, et al.
Publicado: (2022) -
An anti-PD-1–GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy
por: Chan, Sarah, et al.
Publicado: (2022) -
Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas
por: Amoozgar, Zohreh, et al.
Publicado: (2021) -
Impairment of Treg suppression by GITR ligation is effective selectively in the context of a pro-inflammatory tumor microenvironment
por: Zappasodi, Roberta, et al.
Publicado: (2014)